Issues of pay-for-delay settlements are percolating in the courts: California Supreme Court, 3rd Circuit, district courts. Next up: the the 1st Circuit, reviewing the dangerous Loestrin decision. In In re Loestrin 24 FE Antitrust Litigation, the U.S. District Court for the District of Rhode Island issued a concerning ruling on drug patent settlements. The court … Continue reading New article on Loestrin pay-for-delay case…

RIIPL is pleased to announce a lecture by Canadian expert and commentator Mark Warner on April 9 at noon at the law school. Mark Warner will speak about a range of current competition, trade, investment and IP issues involving the pharmaceutical industry in Canada and the implications for U.S. investors and policymakers. He will discuss … Continue reading April 9 noon talk by Mark Warner on pharmaceutical industry…

On January 28, 2015, Judge Mitchell Goldberg of the U.S. District Court for the Eastern District of Pennsylvania denied defendants’ summary judgment motions, sending the second reverse-payment-settlement case to trial. In King Drug Company of Florence v. Cephalon, Judge Goldberg found that plaintiffs “satisfied their burden of presenting evidence of anticompetitive effects” and that there … Continue reading Prof. Carrier article on Cephalon case…

This podcast discusses and elaborates on Professor Carrier’s essay, in which he explores two recent district court decisions that could frustrate the Supreme Court’s recent directive to apply antitrust law to “exclusion payment” patent settlements. The Court’s high-profile Actavis decision set broad guidelines for lower courts on how to assess the settlements, in which a … Continue reading Professor Carrier podcast with Northwestern Law Review…